Biocon floats cardiology division for brand buildingApril 22nd, 2008 - 10:28 pm ICT by admin
Bangalore, April 22 (IANS) Biopharma major Biocon Ltd has set up a stand-alone cardiology division by splitting its cardio-diabetes group to focus on brand building for its flagship product Statix, the company said here Tuesday. “The cardiology business constitutes about 10 percent of the Indian pharma market and is growing at 12 percent annually. The new division will have an all-India presence through a 250-strong field-force,” Biocon chairperson Kiran Mazumdar-Shaw said in a statement.
Besides Statix, which is statin-based, the division will market other products such as Telmisat, Eptifibatide and its recombinant streptokinase product Myokinase for cardio diseases.
The company also commenced phase IIa clinical trials of IN105 dose for type II diabetic. The study, to be completed by August, will provide data for phase IIb trials in the second quarter of this fiscal.
Tags: biocon ltd, cardio diseases, cardiology business, chairperson, clinical trials, diabetes, diabetes group, eptifibatide, flagship product, India, kiran mazumdar shaw, myokinase, pharma, phase iia, phase iib, presence, second quarter, streptokinase